MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian Cancer



Status:Recruiting
Conditions:Ovarian Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/26/2018
Start Date:October 19, 2018
End Date:October 2035
Contact:Payal D Shah, MD
Email:PennCancerTrials@emergingmed.com
Phone:855-216-0098

Use our guide to learn which trials are right for you!

Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase I study to establish safety and feasibility of intraperitoneally administered
lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as
lymphodepleting chemotherapy

This is a Phase I study evaluating the safety and feasibility of intraperitoneally
administered lentiviral transduced MOv19-BBz CAR T cells in 4 cohorts with or without
cyclophosphamide + fludarabine in a 3+3 dose escalation design.

The DLT observation period is 28 days post CAR T cell infusion. The Maximum Tolerated Dose
(MTD) is defined as the dose at which 0 or 1 DLT occurs in 6 evaluable subjects tested within
the dose range of this study.

Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced
MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.

Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced
MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting
chemotherapy with cyclophosphamide + fludarabine.

Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz
CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with
cyclophosphamide + fludarabine.

Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced
MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be
infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.

Inclusion Criteria:

1. Histologically confirmed persistent or recurrent stage II to IV high grade serous
epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Disease can be
platinum-sensitive or platinum-resistant.

2. Failure of at least two prior chemotherapy regimens for advanced stage disease. Prior
therapies against PD-1 or PDL-1 are permissible.

3. Confirmation of tumor aFR expression (≥70% of tumor cells with ≥2+ aFR staining).

4. Subjects must have measureable disease as defined by RECIST 1.1 criteria.

5. Patients with asymptomatic CNS metastases that have been treated and are off steroids
are allowed. They must meet the following at the time of eligibility confirmation by
investigator:

1. No concurrent treatment for the CNS disease

2. No progression of CNS metastasis on brain MRI at screening

3. No evidence of leptomeningeal disease or cord compression

6. Patients ≥ 18 years of age.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

8. Satisfactory organ and bone marrow function as defined by the following:

i. Absolute neutrophil count ≥ 1,000/μl ii. Platelets ≥75,000/μl iii. Hemoglobin ≥ 9
g/dL iv. Total bilirubin ≤ 2.0x the institutional normal upper limit unless secondary
to bile duct obstruction by tumor v. Creatinine ≤ 1.5x the institutional normal upper
limit vi. Albumin ≥2 vii. Serum alanine aminotransferase (ALT) or aspartate
aminotransferase (AST) ≤ 5x the institutional normal upper limit viii. Cardiac
ejection fraction of ≥40% as measured by resting echocardiogram.

9. Blood coagulation parameters: PT such that international normalized ratio (INR) is ≤
1.5 and a PTT ≤ 1.2 time the upper limit of normal unless the patient is
therapeutically anti-coagulated for history of cancer-related thrombosis and has
stable coagulation parameters.

10. Provides written informed consent.

11. Subjects of reproductive potential must agree to use acceptable birth control methods,
as described in protocol Section 4.3.

Exclusion Criteria:

1. High grade serous ovarian, fallopian, or primary peritoneal cancer that is platinum
refractory, defined as disease that has clinical or radiographic progression on
platinum-based chemotherapy, as per the discretion of the treating physician.

2. Patients with symptomatic CNS metastases are excluded.

3. Participation in a therapeutic investigational study within 4 weeks prior to
eligibility confirmation by investigator, or anticipated treatment with another
investigational product while on study. This refers to non-commercially approved
investigational drugs different than those used in this protocol.

4. Active invasive cancer other than ovarian cancers. Patients with active non-invasive
cancers (such as non-melanoma skin cancer, superficial cervical and bladder cancer)
are not excluded.

5. HIV infection

6. Hepatitis B or hepatitis C infection

7. Active autoimmune disease (including but not limited to: systemic lupus erythematosus,
Sjogren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory
bowel disease, etc.) requiring immunosuppressive therapy within 4 weeks prior to
eligibility confirmation by investigator, with the exception of thyroid replacement.

8. Patients with active and uncontrolled infection.

9. Planned concurrent treatment with systemic high dose corticosteroids. Patients may be
on a stable low dose of steroids (<10mg equivalent of prednisone). Corticosteroids
treatment as anti-emetic prophylaxis on the day of lymphodepleting chemotherapy
administration is allowed per institutional guidance.

10. Patients requiring supplemental oxygen therapy.

11. Prior therapy with lentiviral gene modified cells.

12. History of allergy or hypersensitivity to study product excipients (human serum
albumin, DMSO, and Dextran 40)

13. Any ascites requiring therapeutic drainage within 4 weeks prior to eligibility
confirmation by investigator.

14. Pregnant or breastfeeding women.

15. Presence of any other condition that may increase the risk associated with study
participation or may interfere with the interpretation of study results, and, in the
opinion of the investigator, would make the patient inappropriate for entry into the
study.
We found this trial at
1
site
Philadelphia, Pennsylvania 19104
Phone: 855-216-0098
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials